Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2008

View Archived Issues

Recent patent literature reports novel anticancer compounds

Yi-Gan San studied in dementia, tardive dyskinesia and borderline personality disorder

VaxGen and Raven terminate merger agreement

Cardiac-specific MAP kinase protects against cardiac ischemia in vitro and in vivo

Evotec and Ono sign agreement to identify compounds against a protease target

Encouraging results reported in first clinical trial of efficacy for GFT-505

Positive phase III data reported for new GnRH blocker degarelix

Avanir to raise gross proceeds of USD 40 million in a registered direct offering

MethylGene enters agreement with Otsuka for small-molecule kinase inhibitors

MPA requests additional information prior to initiation of Tripeps' ChronSeal phase II study

Thallion defers start date of phase II/III clinical trial of Shigamabs by six months

Evotec reports preliminary findings from study of EVT-101 in healthy volunteers

Seattle Genetics initiates second phase I clinical trial of SGN-35 in Hodgkin's lymphoma

New therapeutic agents for diabetic nephropathy described in recent Kowa patent

Recent Amgen and Kyowa Hakko patents disclose novel analgesic agents

IMPACT1 study demonstrates efficacy of Berinert P in hereditary angioedema

DJ-1 provides neuroprotection against oxidative stress

Effects on survival seen with EGF vaccine in non-small cell lung cancer patients

Lilly commences phase III LY-450139 trial for Alzheimer's disease

NeuroSearch initiates phase I NSD-788 study for anxiety and depression

Synosia Therapeutics commences phase II rufinamide trial for general anxiety disorder

Protectan CBLB-502 shows mitigation of hematopoietic damage post-radiation

UCB reports phase II results for CDP-791 in non-small cell lung cancer

Phase I/II trial in CF patients begins for Humaneered antibody against P. aeruginosa infections

NeoPharm enrolls first patients in phase II cancer trial of liposomal paclitaxel

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...